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Objectives. This study sought to determine the long-term effects
of continuous infusion of epoprostenol (epo) therapy on survival
and pulmonary artery pressure in patients with primary pulmo-
nary hypertension (PPH).
Background. PPH is a progressive disease for which there are
few effective therapies.
Methods. Patients with PPH and New York Heart Associa-
tion functional class III or IV symptoms of congestive heart
failure underwent right heart catheterization and Doppler-
echocardiography to measure the maximal systolic pressure gra-
dient between the right ventricle and right atrium (DP) and
cardiac output (CO). Doppler-echocardiography and catheteriza-
tion data were compared. Patients were followed up long term with
Doppler-echocardiography.
Results. Of 69 patients who went on to receive epo, 18 were
followed up for >330 days (range 330 to 700). During long-term
follow-up, there was a significant reduction in DP, which de-
creased from 84.1 6 24.1 to 62.7 6 18.2 (mean 6 SD, p < 0.01).
A Kaplan-Meier plot of survival of our study patients demon-
strated improved survival compared with that of historical control
subjects. The 1-, 2- and 3-year survival rates for our patients were
80% (n 5 36), 76% (n 5 22) and 49% (n 5 6) compared with 10-
(88%, n 5 31), 20- (56%, n 5 27) and 30-month (47%, n 5 17)
survival rates in historical control subjects.
Conclusions. Patients receiving continuous infusion of epo for
treatment of PPH experience a decrease in pulmonary artery
pressure. Long-term follow-up of this single-center patient group
demonstrated improved long-term survival during epo therapy
compared with that in historical control subjects and confirms
predicted improved outcomes based on shorter follow-up periods.
(J Am Coll Cardiol 1997;30:343–9)
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Patients with primary pulmonary hypertension (PPH) pose a
difficult management problem. There are few effective thera-
pies. The disease is progressive, with increasing pulmonary
vascular resistance (PVR) and pressures, resulting in right
heart failure, dyspnea and decreasing functional status. Un-
treated, the mortality rate is substantial, and life expectancy
after the development of congestive heart failure (CHF) can
be measured in months. In a group of 90 patients with PPH
referred for heart-lung transplantation, the mean survival from
diagnosis was 42.9 6 42.6 months, with a symptom duration of
65.9 6 47.4 months (1). In a national registry of 194 patients
from 32 centers with PPH, the median survival was 2.8 years
(2). In patients with a cardiac index ,2 liters/min per m2, the
median survival was 17 months, and if the right atrial pressure
(RAP) was .20 mm Hg, it was 1 month without therapy. Using
this hemodynamic data (RAP, mean pulmonary artery pres-
sure and cardiac index), equations were derived to predict
mortality (2). Over the past 30 years, a variety of agents have
been studied as potential therapies for PPH. Hydralazine,
nitroprusside and diazoxide have all been ineffective because
of their profound effects on systemic vascular resistance and
blood pressure, limiting their use (3). Work by Rich and
Brundage (4), using calcium channel blocking agents, demon-
strated sustained beneficial effects, including a long-term re-
duction in PVR. However, only ;25% of patients given either
diltiazem or nifedipine responded. These agents could not be
safely used in patients who had already developed significant
CHF.
Epoprostenol (epo), a prostacyclin analogue, has been
studied as an agent to lower pulmonary artery pressures in
patients with PPH. In an 8-week randomized study, Rubin et
al. (5) demonstrated short-term benefits, resulting in a lower-
ing of pulmonary resistance and an improvement in cardiac
output (CO). A prospective, nonrandomized, long-term study
From the *Harbor-UCLA Medical Center, Saint John’s Cardiovascular
Research Center, Torrance; †University of California Los Angeles School of
Medicine, Los Angeles; and ‡St. Mary’s Medical Center, Long Beach, California;
§Second Teaching Hospital, Fourth Military Medical University, Xi’an, People’s
Republic of China; \Loma Linda University School of Medicine, Loma Linda,
California; and ¶Gramercy Cardiology Diagnostic Services, New York, New
York. This study was funded in part by Grant 007083-00 from Burroughs-
Wellcome, Triangle Park, North Carolina and the Saint John’s Cardiovascular
Research Center, Torrance, California.
Manuscript received October 10, 1996; revised manuscript received April 7,
1997, accepted April 24, 1997.
Address for correspondence: Dr. Shelley Shapiro, Cardiology Division,
Harbor-UCLA Medical Center, 1000 West Carson Street RB-2, Torrance,
California 90509.
JACC Vol. 30, No. 2
August 1997:343–9
343
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00187-3
of patients who participated in the short-term randomized
study demonstrated sustained benefit after 1 year (6). Improve-
ment in hemodynamic variables, quality of life and survival at
12 weeks was confirmed by a larger prospective, multicenter
randomized study (7) in 81 patients comparing epo with
conventional therapy. Exercise tolerance improved and corre-
lated with changes in pulmonary pressures (7). There was a
highly significant improvement in survival, even over 12 weeks.
Thus, epo appears to prolong life in patients with PPH and to
improve their functional status. The drug is continuously
administered by infusion pump through a permanent indwell-
ing central venous catheter to patients on an outpatient basis.
Little is known about the effect on pulmonary artery pressure
and CO over time in patients treated with epo. Barst et al. (6)
followed up 18 patients with repeat right heart catheterization
at 1 year. However, repeated invasive testing with right heart
catheterization is expensive, uncomfortable and potentially
risky because of the high pulmonary pressures.
Doppler-echocardiography has been used by investigators
to estimate right heart pressures using the modified Bernoulli
equation (8,9). Hatley and Angelsen (10) used the continuity
equation to measure CO in a variety of clinical settings. We
therefore sought to determine whether noninvasive studies
using Doppler-echocardiography could provide adequate he-
modynamic measurements in patients with PPH and then to
evaluate changes in pulmonary artery pressures and cardiac
function over time in patients treated with continuous infusion
of epo. We first compared our noninvasive methods of esti-
mating right-sided pressures with catheterization data and then
followed up patients noninvasively with repeated measures of
right-sided pressures and CO.
Methods
Patients. Patients with New York Heart Association func-
tional class III or IV symptoms of CHF were referred because
of a probable diagnosis of PPH. Before referral, patients
underwent screening by their referring physicians to exclude
other potential causes of pulmonary hypertension. These
screening studies included chest radiograph, pulmonary func-
tion tests, ventilation perfusion scans and echocardiograms.
Exclusion criteria included evidence of emboli on ventila-
tion perfusion scans, airway disease on pulmonary function
tests, although mild reduction of the pulmonary diffusion
capacity or gas transfer factor for carbon monoxide and lung
volumes were permitted; valvular heart disease (mitral);
congenital heart disease; or left ventricular dysfunction on
Doppler-echocardiography. Although the presence of mildly
elevated antinuclear antibodies was permitted, patients with
specific autoimmune diseases were excluded. Right heart
catheterization was performed to measure pulmonary artery
pressure, PVR and CO and to confirm the diagnosis. A mean
pulmonary artery pressure .25 mm Hg was required at
catheterization. Patients with other known causes of secondary
pulmonary hypertension were excluded. Patients who were of
child-bearing potential who were using an acceptable form of
contraception were included in the study. Enrollment criteria
and dosage adjustment protocol remained unchanged through-
out the study.
Patients who were subsequently enrolled in the infusion
protocol and were followed up locally at Harbor-UCLA Med-
ical Center (HUMC) underwent repeat echocardiography on
an outpatient basis at clinical follow-up. Patients who were
followed up by their referring source had repeat studies
performed when they returned to HUMC for follow-up. Their
initial hemodynamic and echocardiographic data were used for
baseline comparisons. Follow-up noninvasive measurements
made at HUMC were used for long-term comparisons. The
initiation of routine Doppler-echocardiographic measure-
ments at the start of therapy began in 1993 after the enrollment
of 13 patients who were only studied invasively at the time of
enrollment. Patients enrolled before the use of Doppler-
echocardiography as a routine part of the protocol underwent
outpatient noninvasive studies after they were added to the
protocol and are therefore included in the long-term follow-up
data but not in comparisons of short-term or baseline data.
Right heart catheterization. Right heart catheterization
was performed using a balloon flow-directed catheter placed in
the pulmonary artery under fluoroscopy. Hemodynamic mea-
surements of right atrial, right ventricular and pulmonary
artery pressures were performed and recorded using a physi-
ologic recorder. Thermodilution CO was measured in tripli-
cate and averaged.
Total PVR. Total PVR was estimated using the following
formula: Total PVR 5 (Mean pulmonary artery pressure)/CO.
In many of the patients, pulmonary capillary wedge pressures
could not be adequately obtained, and total PVR was therefore
used.
Transthoracic echocardiograms (Doppler-echocardiography).
Transthoracic echocardiograms were obtained within 15 min
of invasive measurements to measure tricuspid regurgitant
velocities using continuous wave Doppler. Color flow Doppler
imaging was used to guide alignment of the continuous wave
Doppler cursor with the regurgitant jet. The technician manip-
ulated the probe to maximize the velocity obtained by finding
the largest jet and visually aligning the continuous wave with
Abbreviations and Acronyms
CHF 5 congestive heart failure
CO 5 cardiac output
epo 5 epoprostenol
HUMC 5 Harbor-UCLA Medical Center
NIH 5 National Institutes of Health
PPH 5 primary pulmonary hypertension
PVR 5 pulmonary vascular resistance
RAP 5 right atrial pressure
DP 5 right ventricular pressure gradient (difference between right
ventricular and right atrial pressures)
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the color flow signal. No angle correction was used. The
Doppler measurements were made from the right ventricular
inflow, parasternal short-axis and apical four-chamber views.
The highest velocity was reported. The right ventricular pres-
sure gradient was calculated using the modified Bernoulli
equation (9,10): DP 5 4V2, where V 5 tricuspid regurgitant
velocity; and DP 5 pressure gradient between the right ventri-
cle and right atrium.
CO. CO was obtained by measuring flow across the left
ventricular outflow tract during systole. Flow was measured at
the level of the aortic valve from the apical five-chamber view.
The velocity time integral (VTI), the summation of flow during
the time period, was obtained by integrating the pulsed wave
systolic flow signal over the duration of systolic flow: A 5
p(D/2)2 where A 5 aortic outflow tract area; D 5 diameter of
left ventricular outflow tract, and VTI 3 A 3 Heart rate 5 CO
(8). Measurements were performed in triplicate and averaged.
Noninvasive follow-up. Patients underwent Doppler-
echocardiography with color flow and continuous wave Dopp-
ler at follow-up clinic visits according to the frequency of
clinic follow-up. They generally averaged three Doppler-
echocardiography evaluations/year. CO, DP and RAP were
measured in supine subjects at rest by the same methods as
those used after catheterization.
Drug administration and titration. The patients received
epo as a continuous intravenous infusion. The initial maxi-
mal dose was determined by titrating to symptoms over 24 to
48 h: nausea, headache and jaw pain or to a drop in systemic
blood pressure .10 mm Hg. Pulmonary artery pressures
obtained by cardiac catheterization or estimated by Doppler-
echocardiography were not used for dosing. After the initial
infusion, a Hickman or Broviac catheter was placed in a central
vein, and the patient and family were trained in the use of a
portable battery-operated infusion pump for outpatient con-
tinuous infusion of the drug. During long-term follow-up, the
dose of epo was adjusted according to symptoms (dyspnea,
declining exercise tolerance and or side effects) after consul-
tation with the center nurse and physician. Side effects in-
cluded lower extremity nonpruritic rashes, jaw pain, headache,
diarrhea, foot pain and lower extremity pain, which were not
indications for drug termination. Worsening exercise tolerance
and subjective shortness of breath were also used to increase
the dosage in patients who were without side effects. In
general, the dosage was increased to 1 to 2 ng/kg body weight
per min every 2 months in most patients. The same method
for dosage adjustment was used throughout the study. The
dosage changes (long term) were not based on the results of
the noninvasive Doppler-echocardiographic measurements
of DP or CO. Dosages at follow-up ranged from 2 to 62 ng/kg
per min.
The study protocol was approved by the institutional review
board of HUMC, and all patients provided written informed
consent.
Statistical methods. Data were stored in a PC-based data
spreadsheet. Analysis was performed using Sigma Stat (Jandel
Corp.), a PC-based statistical package. Paired Student t tests
and signed rank tests were performed. Results are presented as
mean value 6SD; p # 0.05 was considered statistically signif-
icant.
A Kaplan-Meier observed survival probability curve for the
study patients was constructed for comparison with survival
data from historical control subjects from the National Insti-
tutes of Health (NIH) registry (2) (n 5 31) and with data from
Barst et al. (6). (Note that the data of Barst et al. were
generated using a proportional hazards regression model
based on hemodynamic variables and an equation developed
from the NIH registry.)
Results
Demographics and baseline hemodynamic variables.
Seventy-three patients were initially evaluated (11 to 65 years
old; 54 women). Four patients who underwent initial right
heart catheterization did not go on to receive continuous
outpatient infusion. One was excluded because of refusal to
undergo long-term medical therapy and one because his
pulmonary arterial pressure at catheterization was near nor-
mal. Of the remaining patients, a total of 69 went on to receive
epo infusions and formed our outpatient study cohort. Forty-
nine patients underwent right heart catheterization, with con-
comitant Doppler-echocardiographic studies at the initiation
of therapy. Eighteen patients were followed up .330 days
during epo infusion (range 330 to 480). There were no
significant differences in baseline clinical variables (age,
gender, functional class, catheterization data) between the
returning patients followed up with repeat Doppler-
echocardiographic evaluations and those followed up locally
by their referring physicians and only returned annually for
follow-up.
At the time of initial evaluation, all patients were in
functional class III or IV. The average RAP was 14 mm Hg,
with an average CO of 3.6 liters/min. Mean pulmonary artery
systolic pressure was 99.8 6 25.6 mm Hg. Thirty-seven patients
had right heart failure with an RAP .10 mm Hg. At the time
of evaluation, mean RAP for these patients was 17.4 6
3.9 mm Hg, and mean CO was 3.3 6 1 liters/min. For the 21
patients without right heart failure, mean RAP was 7.1 6
2.4 mm Hg, with a mean CO of 4.1 6 1.3.
We compared baseline data for patients who died (n 5 14)
or who underwent transplantation (n 5 10) with that for the
total cohort. On average, patients who underwent transplan-
tation had slightly higher pulmonary artery systolic pressures
(107.3 6 18 vs. 99.8 mm Hg). The mean systolic blood pressure
of 113.6 6 12 and CO (determined by thermodilution) of 3.5
were slightly lower than the values obtained for the total cohort
and the subgroup who died, but these differences were not
statistically significant.
Comparison between right heart catheterization and
Doppler-echocardiographic measurements. Pressure gradi-
ents (DP) and COs correlated well with Swan-Ganz catheter
data in patients who were studied both invasively and nonin-
vasively at the initiation of therapy. Figure 1 (left) demon-
345JACC Vol. 30, No. 2 SHAPIRO ET AL.
August 1997:343–9 PPH: EFFECTS AND SURVIVAL WITH EPOPROSTENOL
strates the correlation between measurements of DP measured
by right heart catheterization and Doppler-echocardiography
using the tricuspid regurgitant velocity and the Bernoulli
equation in 49 patients (r 5 0.85, p , 0.0001). Figure 1 (right)
demonstrates the correlation between Doppler-echocardiography
and right heart catheterization CO measurements in 43 pa-
tients (r 5 0.74, p , 0.0001).
Short-term changes in hemodynamic variables resulting
from epo infusion. The effects of epo on hemodynamic vari-
ables could be discerned within the first 24 to 48 h after
stabilization with an acceptable dose. Systemic blood pressure
dropped from a mean of 122 6 18 to 117 6 16 mm Hg (p ,
0.006, n 5 49). There was a similar but small drop in diastolic
blood pressure from 76 6 12 to 72 6 11 mm Hg (p 5 0.006).
Mean heart rate increased from 85 6 11 to 90 6 13 beats/min
(p , 0.005). The thermodilution CO increased from 3.6 6 1.2
to 4.4 6 1.4 liters/min (p , 0.0001). This change in CO could
not be explained by the increase in heart rate only but reflected
an increase in stroke volume, which increased from 41.5 to
47.1 ml in 43 of 49 patients (p , 0.001). CO data were not
available in 6 of the 49 patients with short-term study data. In
contrast, the changes in pulmonary artery systolic and diastolic
pressures were not statistically significant (systolic: 102 6 23 to
99 6 23 mm Hg; diastolic: 44 6 18 to 43 6 16 mm Hg). There
was a significant decrease in RAP measured by catheterization,
from 14 6 6 mm Hg before to 12 6 6 mm Hg after epo (p 5
0.0063). Total PVR before epo was 31.8 6 12.5 and decreased
significantly to 25.1 6 9.0 after epo (p , 0.001, signed rank
test). The initial responses to epo were similar in the transplant
recipients, the patients who died and the total group that
received epo.
Thirteen of 18 patients with long-term follow-up (.270
days) also had Doppler-echocardiography performed at the
initiation of therapy. A short-term decrease in DP $10% was
seen in 6 of 13 patients, 5 of whom demonstrated a persistent
long-term reduction in DP, and all 6 had a persistent decrease
in the DP/CO ratio. However, five of seven patients without a
short-term decrease in DP also demonstrated a persistent
decline in DP, and six of seven had a reduction in the DP/CO
ratio. Therefore, the absence of a short-term change in DP did
not predict the long-term effects of epo in this group of
patients. A short-term drop in the DP/CO ratio of 15% was
also not predictive of a long-term response.
Long-term follow-up of patients. Of a total of 69 patients
who went on to receive epo, 13 have died. One patient died
during the initial 24-h infusion, and one discontinued therapy
after several months because of depression. This patient
subsequently died 4 months after stopping the infusion. Of
nine patients who underwent single-lung transplantation, three
died. Of the remaining patients taking epo, eight died of
progressive right heart or renal failure. A total of 56 patients
remain alive, many of whom are being followed up at our
facility with repeated noninvasive evaluations of cardiac
function and pulmonary pressure gradients. Of this group,
18 patients have undergone follow-up with Doppler-
echocardiography during long-term epo infusion .330 days.
We used DP for the follow-up echocardiographic hemody-
namic measurements. Echocardiographically derived hemody-
namic measurements made in patients between 330 and 480
days during therapy were compared with baseline measure-
ments. There was a significant reduction in DP, which dropped
from 84.1 6 24.1 to 62.7 6 18.2 mm Hg (p , 0.01). Figure 2
graphically displays the long-term changes in DP over several
time points for all the patients with long-term follow-up .330
Figure 1. Left, Display of correlation between DP obtained echocar-
diographically (Echo DP) and DP obtained by measuring the right
atrial and right ventricular pressures at catheterization (Cath DP) and
computing the difference. Right, Correlation of CO measured using
thermodilution at catheterization (Cath CO) and calculated CO (Echo
CO) generated using the aortic outflow diameter and aortic flow.
Circles 5 individual patients; Solid lines 5 95% confidence intervals.
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days. The overall trend was a continued reduction in DP over
time. Figure 3 demonstrates the changes in the ratio of DP to
CO for 17 patients in whom CO could be adequately measured
noninvasively. The ratio of DP to CO decreased significantly
from 22.8 6 9.4 to 14.9 6 6.5 (p , 0.01), suggesting a reduction
in PVR. These results suggest that over time, the initial
improvements in hemodynamic variables are maintained or
enhanced.
A larger group of patients (n 5 25) have been followed up
for 90 to 190 days (mean 141 6 26). A comparison of their
baseline DP to DP measured between 90 and 190 days demon-
strated a drop in DP from 86.4 6 25.7 to 68.6 6 24 mm Hg (p ,
0.001). Similarly, CO increased from 4.0 6 1.22 to 4.7 6 1.27
liters/min (p , 0.02).
Survival. A Kaplan-Meier plot of survival is shown in
Figure 4. Patients who underwent transplantation were cen-
sured at the time of transplantation. This graph demonstrates
the improved survival in this severely compromised patient
group. The 1-, 2- and 3-year survival rates for our patients were
80% (n 5 36), 76% (n 5 22) and 49% (n 5 6) compared with
10- (88%, n 5 31), 20- (56%, n 5 27) and 30-month (47%, n 5
17) survival rates in historical control subjects (6), which
confirms the predicted survival proposed by Barst et al. (6),
also shown.
Relation between clinical features and response to epo.
Pulmonary hypertension is a pleomorphic disease whose true
etiology is unclear. Although the patients were all considered
to have PPH as the etiology of their elevated pulmonary artery
pressures and symptom complexes, they could be classified into
several broad groups: antinuclear antibody positive (n 5 5),
mild underlying lung disease (n 5 1), hepatic disease (n 5 7),
previous drug abuse (n 5 10) and no associations (n 5 46).
There was no difference among the groups in their response to
epo, although the numbers are small.
Discussion
Survival. This study provides information on the long-term
follow-up of patients who have been treated with one of the
few effective agents for stabilizing PPH. The patients in our
Figure 3. Ratio of DP to CO (obtained echocardiographically) before
initiation of epo infusion and after a time period of between 330 and
480 days, displayed for each individual patient (n 5 17). Lines connect
the preinfusion value with the value obtained between 330 and 480
days. Data shown are mean value (x) 6 SD.
Figure 2. Change in DP measured echocar-
diographically over time (days) for the 18
patients for whom long-term data .330 days
are available. Each point represents the mea-
surement for an individual patient; solid lines
connect measurements made in the same
patient. Because of patient schedules, the
measurements were not made at the same
time interval or frequency in all patients. The
trend is toward a gradual and sustained re-
duction in DP and therefore in pulmonary
artery pressure.
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study lived longer and improved clinically, long enough for
some to ask to be removed from the transplant list. Although
this was not a blinded study, nor was there a control group (i.e.,
patients with PPH referred to us and followed up without
prostacyclin therapy), there are historical data from the NIH
registry and groups of patients treated with other agents
(calcium channel blockers). Compared with historical control
subjects, patients treated with prostacyclin appear to have a
markedly improved outcome. Our data on long-term follow-up
also support and match the model of survival proposed by
Barst et al. (6), predicting improved long-term outcome in
patients treated with continuous intravenous prostacyclin. The
NIH data demonstrated a clear relation between hemody-
namic variables and survival. Using the relation between
hemodynamic variables and survival, Barst et al. (6) demon-
strated short-term improvement in hemodynamic variables and
survival and predicted longer term survival benefits. We saw a
similar relation between hemodynamic variables and outcome.
Although improvement in survival has been demonstrated
in patients responding to calcium channel blockers, the percent
of adult responders is small. Many of the patients in the
present study could not be treated with calcium channel
blockers because of the inability to tolerate or respond hemo-
dynamically to calcium channel blockers or because of the
danger of using them in the setting of severe right heart failure.
Doppler-echocardiography. We described a method for
noninvasive long-term follow-up of patients with PPH and
demonstrated the relation between invasive and noninvasive
measures as well the results of the long-term treatment. Most
of the published studies in patients with PPH have depended
on invasive measurements to determine the response to ther-
apy. This difficulty in monitoring precludes frequent hemody-
namic assessment and therefore the use of hemodynamic
measurements to direct further adjustments in the rate of
infusion. In the present study, there was no perspective titra-
tion of dose to meet hemodynamic end points. We were able to
show good correlation between invasive and noninvasive mea-
surements of right-sided pressure gradients and CO. Thus,
Doppler-echocardiography may enable the use of hemody-
namic measures to adjust dosage more effectively, with firmer
end points, although this will need to be tested prospectively.
Although right ventricular pressure can be determined
using the Bernoulli equation, assuming an RAP of 10 mm Hg,
this assumption was not valid for our patients. The wide range
of RAP (3 to 29 mm Hg) at the time of catheterization,
including a markedly elevated RAP in many patients, invali-
dates the use of an average or presumed RAP. Repeat
measurement of jugular venous pressure would require physi-
cian intervention at the time of echocardiography. Although
such intervention may be feasible in the clinical setting, it
would have biased our Doppler-echocardiographic data. Esti-
mation of RAP using caval size and response to respiration was
not feasible in some patients. We therefore chose to compare
DP determined echocardiographically and by catheterization
and were able to demonstrate a decline in DP and an increase
in CO with therapy. Our patients almost uniformly demon-
strated a reduction in RAP as the pulmonary artery pressure
declined over time. Thus, the drop in pulmonary artery pres-
sure was probably greater than that indicated by the reduction
in DP.
The determination of DP required meticulous echocardio-
graphic and Doppler imaging. Alignment of the tricuspid
regurgitant jet with the Doppler beam was critical to avoid
underestimation of the gradient, creating a false impression
that the patients were responding to therapy. Many of the
patients had an enlarged right atrium and eccentric jets, which
necessitated off-angle views and careful tracking of the color
flow Doppler jet to align the continuous wave beam.
Dosage adjustment. We showed that the use of epo re-
sulted in beneficial hemodynamic results over time that were
achieved by almost monthly titration of the dosages. The
adjustments in dosage were made in conjunction with a nurse
according to protocol-defined symptoms. Patients appeared to
develop a “tolerance” to the drug, with a decrease in side
effects and an increase in symptoms of pulmonary hyperten-
sion (i.e., shortness of breath and reduction in exercise toler-
ance). This drug tolerance may explain the increases in DP
seen in some patients. Because echocardiographic measures
were not used to adjust the dosage of epo we do not know
whether we could have reversed the pressure increase by
adjusting the dose upward. We also do not know whether the
increasing pulmonary artery pressures were due to drug toler-
ance or to progression of the disease.
Patients who tolerated the initial infusion received long-
term therapy regardless of the initial hemodynamic response,
Figure 4. Kaplan-Meier survival plot for study patients (HUMC)
displayed with the estimated survival probabilities from the NIH
registry and from Barst et al. (6). Numbers below the graph are
subjects at risk for each cohort. Patients who underwent transplanta-
tion were censured at the time of transplantation. PGI2 5 prostacyclin.
Modified, with permission, from Barst et al. (6).
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in contrast to studies that have limited drug therapy to
responders (11,12). Our data on a subset of patients who were
evaluated noninvasively at the initiation of therapy and then
followed up with Doppler-echocardiography fail to demon-
strate a relation between initial hemodynamic response and
long-term reduction in DP. In fact, almost all the patients
ultimately responded with a reduction in right-sided pressures.
In the study by Raffy et al. (11), response to epo was used to
predict response to calcium channel blockers. Because our
patients were too sick to receive a trial of these agents, we are
unable to confirm the predictive value of an initial epo infusion
for a response to calcium channel blockers.
Other limitations. PPH is a rare disease. Patients who were
very ill (functional class III or IV) came from great distances to
start epo therapy and received their day to day care locally.
Thus, hemodynamic follow-up was variable and for some
patients, very limited. Although by phone and clinical follow-
up, patients appeared to do better, formal exercise testing and
quantitative quality of life measurements were not performed.
The patients were clinically assessed, but the study was not
designed to measure changes in functional class or clinical
symptoms as end points; these end points will be explored in
other studies. Despite these limitations, we believe that our
data support the premise that epo improves quality of life in
patients with PPH and reduces pulmonary artery pressures.
Future goals. Our study provides the basis for addi-
tional approaches to current management strategies for
patients receiving epo. We plan to incorporate Doppler-
echocardiographic criteria in the clinical algorithm that we use
to adjust the dose of epo to maximize the improvement in CO
and reduction in pulmonary artery pressures. This approach
might allow more aggressive reduction in pulmonary pressures.
The development of a strategy that uses hemodynamic mea-
surements is particularly important because although we dem-
onstrated reduction in DP over time, not all patients responded
equally. It is unclear whether the patients without a reduction
in DP might have benefited clinically if the doses were adjusted
to achieve an adequate reduction or whether there are bene-
ficial effects of epo beyond those measured by changes in
pressure.
It could be argued that measuring pulmonary resistance
would be better than DP to assess the drug effect; however,
even with right heart catheterization, measurement of wedge
pressure is often unreliable. Thus, the use of DP remains a
measure of pulmonary pressure and, indirectly, resistance.
Conclusions. Transthoracic echocardiography using Dopp-
ler can be used to follow up patients undergoing treatment for
PPH. The estimates of right ventricular pressure gradients
correlate well with invasive measurements. Therapy with epo
appears to cause a gradual reduction in right ventricular
pressures and an increase in CO over time. These changes are
accompanied by a reduction in clinical symptoms of right heart
failure. Treatment with epo prolongs life in patients with PPH
and can be safely used in patients with right heart failure who
cannot tolerate calcium channel blockers or in whom calcium
channel blocker therapy has failed. Longer follow-up of pa-
tients receiving epo will be needed to determine whether
hemodynamic benefits persist and whether these changes are
associated with maintenance of clinical improvement. Finally,
we propose that studies be designed to use Doppler-
echocardiography as a tool not just to monitor pulmonary
pressures in patients with PPH, but to adjust the dosage of
prostacyclin toward a desired hemodynamic effect.
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